---
title: Stable Ischemic Disease
author: J. Austin Straley, DO
date: 2024-03-16
updated: 2024-04-25
categories:
  - Cardiology
---
## General

- Aka "Chronic Stable Angina"

## Management

- Stop Smoking, Low-fat diet, 30-60 minutes of exercise 5-7 days a week
- Weight loss, BP management
- Goals of Pharmacologic Management
    - Reduce risk of MI/CV death
        - Anti-platelet
            - Aspirin or clopidogrel
        - [4S: Statins reduce Death, MI, Revasc in Angina/MI patients][8]
            - [SATURN: Crestor better LDL reduction, no better mortality than Lipitor][9]
            - Atorvastatin (Lipitor)
                - [Muscle toxicity w/concurrent Amiodarone use (0.7%)][10]
            - Rosuvastatin (Crestor)
                - [Crestor FDA (Renal Dosing)][11]
                - [Crestor to prevent vascular events in patients with elevated CRP][12]
            - Side Effects
                - [Statin induced diabetes and its clinical implications][13]
                - [Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis][14]
                - [Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials][15]
                - [Statin-Associated Myopathy][16]
                    - [Adverse events with concomitant amiodarone and statin therapy][17]
                - [Asymptomatic hypothyroidism and statin-induced myopathy][18]
        - LVEF <40% or prior MI
            - Beta-Blockers
        - LVEF <40%, T2DM, HTN. CKD
            - ACEI/ARB
    - Symptom alleviation and improvement of QOL
        - Beta-Blockers as initial therapy
        - CCBs or LA-Nitrates if BBs can not be used or are not controlling angina
        - Ranolazine if on maximal tolerable medical therapy
        - [COURAGE: PCI w/BMS in Stable CAD non-superior to medical therapy][19]
        - [In life expectancy <1, discontinuation of statin did not increase 60-day mortality][20]

![Courtesy of Rosenson RS, Hegele RA, Fazio S, Cannon CP. The Evolving Future of PCSK9 Inhibitors. J Am Coll Cardiol. 2018 Jul 17;72(3):314-329. doi: 10.1016/j.jacc.2018.04.054. Epub 2018 Jul 9. PMID: 30012326.](/assets/images/fellowship-guide/cards/chest-pain/LDL_ACS_CAD.jpg)

![Courtesy of Riordan M, Schuetze K.](/assets/images/fellowship-guide/cards/stable-ischemic-disease/Vascular-EA-Schuetze-Riordan-Fig1.webp)

## Revascularization (CABG)

- [SYNTAX]: Less CV events at 1 year w/CABG vs. PCI in 3-vessel and/or LM disease[3]
    - 17.8% vs. 12.4%; driven by need for repeat revascularization in PCI group
    - Use of only paclitaxel stents, which have higher rate of angiographic restenosis than either the sirolimus- or everolimus-eluting stents
    - [Five-year outcomes][4]
        - Roughly equivalent unless high Syntax score which favors surgery
- [Syntax Score][5]
    - The SYNTAX score is a grading system that evaluates the complexity and prognosis of patients undergoing percutaneous coronary intervention (PCI)
    - [Calculator][6]
- [Indications for CABG][1]
    - Class 1
        - LM w/complex CAD
        - LM w/Syntax score >33
        - LM w/complex CAD + Syntax score >33 + Suitable Candidate
        - MVCAD w/suitable anatomy + Suitable Candidate + LVEF ($\leq$) 35%
    - Class 2a
        - MVCAD w/suitable anatomy + Suitable Candidate + LVEF ($\geq$) 35%
            - [ISCHEMIA][21], [FAME-2][22], and 10-year updates from the [MASS -II][23] trial showing a reduction in CV mortality
    - Class 2b
    - MVCAD w/suitable anatomy + LVEF >50% (Note PCI also 2b)
    - IMA (internal mammary artery) remains preferred choice for LAD
        - Radial preferred over SVG for 2nd most important vessel (non-LAD)
            - AATS disagrees with this without patient specifiers

## Post-CABG Management

- ~10-20% readmitted within 30 days
- [Consider the 3 "I"s][2]
    - Infectious
        - [Sternal wounds][7]
    - Inflammatory
        - Pericarditis
            - Get TTE, contact primary surgeon
            - May lead to Tamponade
                - Commonly presents early (<7 days)
    - Ischemic
        - Myocardial Infarction
- Dyspnea is common post-operatively
    - Once discharged, new-onset dyspnea should be evaluated for (Most to Least likely):
        - [Pleural effusion (50%), atelectasis, congestive heart failure (13%), pneumonia (2.4%) and pulmonary embolism][24]
        - Diaphragmatic Paralysis
            - Dyspnea at rest or with exertion and supine hypoxemia
            - FVC dropped in the supine position
            - Elevated hemidiaphragm
            - Diagnosis: Confirmed via the “sniff test” under fluroscopy
- 30% develop Atrial Fibrillation
    - Usually self-limiting if new-onset
    - Return to NSR by 6-12 weeks out
- 30% AKI
- 50-70% develop cognitive dysfunction
- Delirium in 73%

[1]: https://www.acc.org/Latest-in-Cardiology/Articles/2022/10/31/13/02/Key-Takeaways-From-the-2021-Coronary-Revascularization-Guidelines
[2]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157999/
[3]: https://www.wikijournalclub.org/wiki/SYNTAX
[4]: https://pubmed.ncbi.nlm.nih.gov/24700706/{:target="_blank"}
[5]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348991/
[6]: https://syntaxscore.org/calculator/start.htm/
[7]: https://www.cmaj.ca/content/cmaj/suppl/2021/05/04/193.19.E689.DC1/191108-view-2-at.pdf
[8]: https://pubmed.ncbi.nlm.nih.gov/7968073/{:target="_blank"}
[9]: https://pubmed.ncbi.nlm.nih.gov/22085316/{:target="_blank"}
[10]: https://pubmed.ncbi.nlm.nih.gov/15860984/{:target="_blank"}
[11]: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021366s040s041lbl.pdf
[12]: https://pubmed.ncbi.nlm.nih.gov/18997196/{:target="_blank"}
[13]: https://pubmed.ncbi.nlm.nih.gov/25210397/{:target="_blank"}
[14]: https://pubmed.ncbi.nlm.nih.gov/21693744/{:target="_blank"}
[15]: https://pubmed.ncbi.nlm.nih.gov/20167359/{:target="_blank"}
[16]: https://pubmed.ncbi.nlm.nih.gov/12672737/{:target="_blank"}
[17]: https://pubmed.ncbi.nlm.nih.gov/15860984/{:target="_blank"}
[18]: https://pubmed.ncbi.nlm.nih.gov/17872677/{:target="_blank"}
[19]: https://pubmed.ncbi.nlm.nih.gov/17387127/{:target="_blank"}
[20]: https://pubmed.ncbi.nlm.nih.gov/20818875/{:target="_blank"}
[21]: https://www.nejm.org/doi/full/10.1056/NEJMoa1915922
[22]: https://pubmed.ncbi.nlm.nih.gov/20733102/
[23]: https://pubmed.ncbi.nlm.nih.gov/25176289/
[24]: https://www.cmaj.ca/content/193/19/E689/tab-related-content/
